Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):482–490. doi: 10.1038/bjc.1996.85

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

S R Wedge 1, J K Porteus 1, B L May 1, E S Newlands 1
PMCID: PMC2074446  PMID: 8595163

Abstract

Depletion of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT) with O(6)-benzylguanine (O(6)-BG) has been widely shown to enhance 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) activity. This study aimed to determine whether temozolomide, a methylating imidazotetrazinone, would similarly benefit from combination with O(6)-BG. Seven human cell lines were examined with AGT activities ranging from <6 fmol mg-1 protein to >700 fmol mg-1 protein. Comparisons with BCNU were made on both single and multiple dosing schedules, since temozolomide cytotoxicity is highly schedule dependent. In single-dose potentiation studies, cells were preincubated with 100 microM O(6)-BG for 1 h, a treatment found to deplete AGT activity by >90% for 24 h. No potentiation of either temozolomide or BCNU cytotoxicity was observed in two glioblastoma cell lines with <6 fmol mg-1 protein AGT. In all other cell lines studied potentiation of BCNU toxicity by O(6)-BG was between 1.6- and 2.3-fold and exceeded that of temozolomide (1.1- to 1.7-fold). The magnitude of this potentiation was unrelated to AGT activity and the relative potentiation of temozolomide and BCNU cytotoxicity was found to be highly variable between cell lines. In multiple dosing studies two colorectal cell lines (Mawi and LS174T) were treated with temozolomide or BCNU at 24 h intervals for up to 5 days, with or without either 100 microM O(6)-BG for 1 h or 1 microM O(6)-BG for 24 h, commencing 1 h before alkylating treatment. Extended treatment with 1 microM O(6)-BG produced greater potentiation than intermittent treatment with 100 microM O(6)-BG. Potentiation of temozolomide cytotoxicity increased linearly in Mawi with each subsequent dosing: from 1.4-fold (day 1) to 4.2-fold (day 5) with continuous 1 microM O(6)-BG. In contrast, no potentiation was observed in LS174T, a cell line that would appear to be 'tolerant' of methylation. Potentiation of BNCU cytotoxicity increased in both cell lines with repeat dosing, although the rate of increase was less than that observed with temozolomide and continuous 1 microM O(6)-BG in Mawi. These results suggest that repeat dosing of an AGT inhibitor and temozolomide may have a clinical role in the treatment of tumours that exhibit AGT-mediated resistance.

Full text

PDF
482

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aida T., Cheitlin R. A., Bodell W. J. Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis. 1987 Sep;8(9):1219–1223. doi: 10.1093/carcin/8.9.1219. [DOI] [PubMed] [Google Scholar]
  2. Ali-Osman F. Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res. 1989 Oct 1;49(19):5258–5261. [PubMed] [Google Scholar]
  3. Baer J. C., Freeman A. A., Newlands E. S., Watson A. J., Rafferty J. A., Margison G. P. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993 Jun;67(6):1299–1302. doi: 10.1038/bjc.1993.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker R. M., Van Voorhis W. C., Spencer L. A. HeLa cell variants that differ in sensitivity to monofunctional alkylating agents, with independence of cytotoxic and mutagenic responses. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5249–5253. doi: 10.1073/pnas.76.10.5249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bodell W. J., Gerosa M., Aida T., Berger M. S., Rosenblum M. L. Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas. Cancer Res. 1985 Aug;45(8):3460–3464. [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993 Apr 15;362(6421):652–654. doi: 10.1038/362652a0. [DOI] [PubMed] [Google Scholar]
  8. Branch P., Hampson R., Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res. 1995 Jun 1;55(11):2304–2309. [PubMed] [Google Scholar]
  9. Brent T. P., Houghton P. J., Houghton J. A. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci U S A. 1985 May;82(9):2985–2989. doi: 10.1073/pnas.82.9.2985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brent T. P. Inactivation of purified human O6-alkylguanine-DNA alkyltransferase by alkylating agents or alkylated DNA. Cancer Res. 1986 May;46(5):2320–2323. [PubMed] [Google Scholar]
  11. Brent T. P., Lestrud S. O., Smith D. G., Remack J. S. Formation of DNA interstrand cross-links by the novel chloroethylating agent 2-chloroethyl(methylsulfonyl)methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts. Cancer Res. 1987 Jul 1;47(13):3384–3387. [PubMed] [Google Scholar]
  12. Carter S. K., Wasserman T. H. The nitrosoureas--thoughts for the future. Cancer Treat Rep. 1976 Jun;60(6):807–811. [PubMed] [Google Scholar]
  13. Catapano C. V., Broggini M., Erba E., Ponti M., Mariani L., Citti L., D'Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res. 1987 Sep 15;47(18):4884–4889. [PubMed] [Google Scholar]
  14. Ceccotti S., Dogliotti E., Gannon J., Karran P., Bignami M. O6-methylguanine in DNA inhibits replication in vitro by human cell extracts. Biochemistry. 1993 Dec 14;32(49):13664–13672. doi: 10.1021/bi00212a035. [DOI] [PubMed] [Google Scholar]
  15. Citron M., Decker R., Chen S., Schneider S., Graver M., Kleynerman L., Kahn L. B., White A., Schoenhaus M., Yarosh D. O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 1991 Aug 15;51(16):4131–4134. [PubMed] [Google Scholar]
  16. D'Incalci M., Taverna P., Erba E., Filippeschi S., Potenza D., Mariani L., Citti L., Catapano C. V. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res. 1991 Jan-Feb;11(1):115–121. [PubMed] [Google Scholar]
  17. Denny B. J., Wheelhouse R. T., Stevens M. F., Tsang L. L., Slack J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994 Aug 9;33(31):9045–9051. doi: 10.1021/bi00197a003. [DOI] [PubMed] [Google Scholar]
  18. Dolan M. E., Corsico C. D., Pegg A. E. Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem Biophys Res Commun. 1985 Oct 15;132(1):178–185. doi: 10.1016/0006-291x(85)91004-6. [DOI] [PubMed] [Google Scholar]
  19. Dolan M. E., Mitchell R. B., Mummert C., Moschel R. C., Pegg A. E. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 1;51(13):3367–3372. [PubMed] [Google Scholar]
  20. Dolan M. E., Morimoto K., Pegg A. E. Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines. Cancer Res. 1985 Dec;45(12 Pt 1):6413–6417. [PubMed] [Google Scholar]
  21. Dolan M. E., Pegg A. E., Hora N. K., Erickson L. C. Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate. Cancer Res. 1988 Jul 1;48(13):3603–3606. [PubMed] [Google Scholar]
  22. Dolan M. E., Pegg A. E., Moschel R. C., Grindey G. B. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993 Jul 20;46(2):285–290. doi: 10.1016/0006-2952(93)90416-t. [DOI] [PubMed] [Google Scholar]
  23. Domoradzki J., Pegg A. E., Dolan M. E., Maher V. M., McCormick J. J. Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1984 Dec;5(12):1641–1647. doi: 10.1093/carcin/5.12.1641. [DOI] [PubMed] [Google Scholar]
  24. Drummond J. T., Li G. M., Longley M. J., Modrich P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science. 1995 Jun 30;268(5219):1909–1912. doi: 10.1126/science.7604264. [DOI] [PubMed] [Google Scholar]
  25. Edwards M. S., Levin V. A., Wilson C. B. Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep. 1980;64(12):1179–1205. [PubMed] [Google Scholar]
  26. Erickson L. C., Laurent G., Sharkey N. A., Kohn K. W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 1980 Dec 25;288(5792):727–729. doi: 10.1038/288727a0. [DOI] [PubMed] [Google Scholar]
  27. Fairbairn L. J., Watson A. J., Rafferty J. A., Elder R. H., Margison G. P. O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol. 1995 Feb;23(2):112–116. [PubMed] [Google Scholar]
  28. Felker G. M., Friedman H. S., Dolan M. E., Moschel R. C., Schold C. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993;32(6):471–476. doi: 10.1007/BF00685892. [DOI] [PubMed] [Google Scholar]
  29. Fishel R., Lescoe M. K., Rao M. R., Copeland N. G., Jenkins N. A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993 Dec 3;75(5):1027–1038. doi: 10.1016/0092-8674(93)90546-3. [DOI] [PubMed] [Google Scholar]
  30. Friedman H. S., Dolan M. E., Moschel R. C., Pegg A. E., Felker G. M., Rich J., Bigner D. D., Schold S. C., Jr Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16;84(24):1926–1931. doi: 10.1093/jnci/84.24.1926. [DOI] [PubMed] [Google Scholar]
  31. Gerson S. L., Berger N. A., Arce C., Petzold S. J., Willson J. K. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. Biochem Pharmacol. 1992 Mar 3;43(5):1101–1107. doi: 10.1016/0006-2952(92)90618-s. [DOI] [PubMed] [Google Scholar]
  32. Gerson S. L., Trey J. E., Miller K., Berger N. A. Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis. 1986 May;7(5):745–749. doi: 10.1093/carcin/7.5.745. [DOI] [PubMed] [Google Scholar]
  33. Gerson S. L., Trey J. E., Miller K. Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1988 Mar 15;48(6):1521–1527. [PubMed] [Google Scholar]
  34. Gerson S. L., Zborowska E., Norton K., Gordon N. H., Willson J. K. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol. 1993 Jan 26;45(2):483–491. doi: 10.1016/0006-2952(93)90086-c. [DOI] [PubMed] [Google Scholar]
  35. Gibson N. W., Hartley J. A., Barnes D., Erickson L. C. Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype. Cancer Res. 1986 Oct;46(10):4995–4998. [PubMed] [Google Scholar]
  36. Goldmacher V. S., Cuzick R. A., Jr, Thilly W. G. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanidine. J Biol Chem. 1986 Sep 25;261(27):12462–12471. [PubMed] [Google Scholar]
  37. Gonzaga P. E., Potter P. M., Niu T. Q., Yu D., Ludlum D. B., Rafferty J. A., Margison G. P., Brent T. P. Identification of the cross-link between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res. 1992 Nov 1;52(21):6052–6058. [PubMed] [Google Scholar]
  38. Goth-Goldstein R. MNNG-induced partial phenotypic reversion of Mer- cells. Carcinogenesis. 1987 Oct;8(10):1449–1453. doi: 10.1093/carcin/8.10.1449. [DOI] [PubMed] [Google Scholar]
  39. Griffin S., Branch P., Xu Y. Z., Karran P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry. 1994 Apr 26;33(16):4787–4793. doi: 10.1021/bi00182a006. [DOI] [PubMed] [Google Scholar]
  40. Griffin S., Karran P. Incision at DNA G.T mispairs by extracts of mammalian cells occurs preferentially at cytosine methylation sites and is not targeted by a separate G.T binding reaction. Biochemistry. 1993 Dec 7;32(48):13032–13039. doi: 10.1021/bi00211a012. [DOI] [PubMed] [Google Scholar]
  41. Grilley M., Welsh K. M., Su S. S., Modrich P. Isolation and characterization of the Escherichia coli mutL gene product. J Biol Chem. 1989 Jan 15;264(2):1000–1004. [PubMed] [Google Scholar]
  42. Hayward I. P., Parsons P. G. Comparison of virus reactivation, DNA base damage, and cell cycle effects in autologous human melanoma cells resistant to methylating agents. Cancer Res. 1984 Jan;44(1):55–58. [PubMed] [Google Scholar]
  43. Holmes J., Jr, Clark S., Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5837–5841. doi: 10.1073/pnas.87.15.5837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Jiang B. Z., Bank B. B., Hsiang Y. H., Shen T., Potmesil M., Silber R. Lack of drug-induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells. Cancer Res. 1989 Oct 15;49(20):5514–5517. [PubMed] [Google Scholar]
  45. Jiricny J., Hughes M., Corman N., Rudkin B. B. A human 200-kDa protein binds selectively to DNA fragments containing G.T mismatches. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8860–8864. doi: 10.1073/pnas.85.23.8860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Karran P., Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res. 1992 Jun 25;20(12):2933–2940. doi: 10.1093/nar/20.12.2933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Karran P., Macpherson P., Ceccotti S., Dogliotti E., Griffin S., Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem. 1993 Jul 25;268(21):15878–15886. [PubMed] [Google Scholar]
  48. Kat A., Thilly W. G., Fang W. H., Longley M. J., Li G. M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6424–6428. doi: 10.1073/pnas.90.14.6424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Lee S. M., Thatcher N., Crowther D., Margison G. P. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer. 1994 Mar;69(3):452–456. doi: 10.1038/bjc.1994.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Lee S. M., Thatcher N., Margison G. P. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991 Jan 15;51(2):619–623. [PubMed] [Google Scholar]
  51. Li G. M., Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1950–1954. doi: 10.1073/pnas.92.6.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Liu L., Allay E., Dumenco L. L., Gerson S. L. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res. 1994 Sep 1;54(17):4648–4652. [PubMed] [Google Scholar]
  53. Marathi U. K., Dolan M. E., Erickson L. C. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15;54(16):4371–4375. [PubMed] [Google Scholar]
  54. Marathi U. K., Kroes R. A., Dolan M. E., Erickson L. C. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15;53(18):4281–4286. [PubMed] [Google Scholar]
  55. Mitchell R. B., Dolan M. E. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993;32(1):59–63. doi: 10.1007/BF00685877. [DOI] [PubMed] [Google Scholar]
  56. Mitchell R. B., Moschel R. C., Dolan M. E. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 1;52(5):1171–1175. [PubMed] [Google Scholar]
  57. Mitra G., Pauly G. T., Kumar R., Pei G. K., Hughes S. H., Moschel R. C., Barbacid M. Molecular analysis of O6-substituted guanine-induced mutagenesis of ras oncogenes. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8650–8654. doi: 10.1073/pnas.86.22.8650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Montgomery J. A., James R., McCaleb G. S., Johnston T. P. The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds. J Med Chem. 1967 Jul;10(4):668–674. doi: 10.1021/jm00316a033. [DOI] [PubMed] [Google Scholar]
  59. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Newlands E. S., Blackledge G., Slack J. A., Goddard C., Brindley C. J., Holden L., Stevens M. F. Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801–805. [PubMed] [Google Scholar]
  61. O'Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., Illingworth R. D., Richards P. G., Kennard C., Colquhoun I. R., Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940–942. doi: 10.1016/s0959-8049(05)80198-4. [DOI] [PubMed] [Google Scholar]
  62. Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., D'Arrigo A., Truong O., Hsuan J. J., Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science. 1995 Jun 30;268(5219):1912–1914. doi: 10.1126/science.7604265. [DOI] [PubMed] [Google Scholar]
  63. Palombo F., Hughes M., Jiricny J., Truong O., Hsuan J. Mismatch repair and cancer. Nature. 1994 Feb 3;367(6462):417–417. doi: 10.1038/367417a0. [DOI] [PubMed] [Google Scholar]
  64. Panella T. J., Smith D. C., Schold S. C., Rogers M. P., Winer E. P., Fine R. L., Crawford J., Herndon J. E., 2nd, Trump D. L. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res. 1992 May 1;52(9):2456–2459. [PubMed] [Google Scholar]
  65. Papadopoulos N., Nicolaides N. C., Liu B., Parsons R., Lengauer C., Palombo F., D'Arrigo A., Markowitz S., Willson J. K., Kinzler K. W. Mutations of GTBP in genetically unstable cells. Science. 1995 Jun 30;268(5219):1915–1917. doi: 10.1126/science.7604266. [DOI] [PubMed] [Google Scholar]
  66. Parsons R., Li G. M., Longley M. J., Fang W. H., Papadopoulos N., Jen J., de la Chapelle A., Kinzler K. W., Vogelstein B., Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 1993 Dec 17;75(6):1227–1236. doi: 10.1016/0092-8674(93)90331-j. [DOI] [PubMed] [Google Scholar]
  67. Pegg A. E., Scicchitano D., Dolan M. E. Comparison of the rates of repair of O6-alkylguanines in DNA by rat liver and bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1984 Sep;44(9):3806–3811. [PubMed] [Google Scholar]
  68. Pieper R. O., Futscher B. W., Erickson L. C. Transcription-terminating lesions induced by bifunctional alkylating agents in vitro. Carcinogenesis. 1989 Jul;10(7):1307–1314. doi: 10.1093/carcin/10.7.1307. [DOI] [PubMed] [Google Scholar]
  69. Plant J. E., Roberts J. J. Extension of the pre-DNA synthetic phase of the cell cycle as a consequence of DNA alkylation in Chinese hamster cells: a possible mechanism of DNA repair. Chem Biol Interact. 1971 Oct;3(5):343–351. doi: 10.1016/0009-2797(71)90014-7. [DOI] [PubMed] [Google Scholar]
  70. Plowman J., Waud W. R., Koutsoukos A. D., Rubinstein L. V., Moore T. D., Grever M. R. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1994 Jul 15;54(14):3793–3799. [PubMed] [Google Scholar]
  71. Potter D. W., Reed D. J. Involvement of FMN and phenobarbital cytochrome P-450 in stimulating a one-electron reductive denitrosation of 1-(2-chloroethyl)-3-(cyclohexyl)-1-nitrosourea catalyzed by NADPH-cytochrome P-450 reductase. J Biol Chem. 1983 Jun 10;258(11):6906–6911. [PubMed] [Google Scholar]
  72. Redmond S. M., Joncourt F., Buser K., Ziemiecki A., Altermatt H. J., Fey M., Margison G., Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 1991 Apr 15;51(8):2092–2097. [PubMed] [Google Scholar]
  73. Sarkar A., Dolan M. E., Gonzalez G. G., Marton L. J., Pegg A. E., Deen D. F. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993;32(6):477–481. doi: 10.1007/BF00685893. [DOI] [PubMed] [Google Scholar]
  74. Scudiero D. A., Meyer S. A., Clatterbuck B. E., Mattern M. R., Ziolkowski C. H., Day R. S., 3rd Relationship of DNA repair phenotypes of human fibroblast and tumor strains to killing by N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1984 Mar;44(3):961–966. [PubMed] [Google Scholar]
  75. Seidenfeld J., Barnes D., Block A. L., Erickson L. C. Comparison of DNA interstrand cross-linking and strand breakage by 1,3-bis(2-chloroethyl)-1-nitrosourea in polyamine-depleted and control human adenocarcinoma cells. Cancer Res. 1987 Sep 1;47(17):4538–4543. [PubMed] [Google Scholar]
  76. Shibata D., Peinado M. A., Ionov Y., Malkhosyan S., Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet. 1994 Mar;6(3):273–281. doi: 10.1038/ng0394-273. [DOI] [PubMed] [Google Scholar]
  77. Silber J. R., Bobola M. S., Ewers T. G., Muramoto M., Berger M. S. O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines. Oncol Res. 1992;4(6):241–248. [PubMed] [Google Scholar]
  78. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  79. Smith M. T., Evans C. G., Doane-Setzer P., Castro V. M., Tahir M. K., Mannervik B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res. 1989 May 15;49(10):2621–2625. [PubMed] [Google Scholar]
  80. Su S. S., Modrich P. Escherichia coli mutS-encoded protein binds to mismatched DNA base pairs. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5057–5061. doi: 10.1073/pnas.83.14.5057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Tano K., Shiota S., Collier J., Foote R. S., Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci U S A. 1990 Jan;87(2):686–690. doi: 10.1073/pnas.87.2.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Tisdale M. J. Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol. 1987 Feb 15;36(4):457–462. doi: 10.1016/0006-2952(87)90351-0. [DOI] [PubMed] [Google Scholar]
  83. Tong W. P., Kirk M. C., Ludlum D. B. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res. 1982 Aug;42(8):3102–3105. [PubMed] [Google Scholar]
  84. Tong W. P., Kirk M. C., Ludlum D. B. Molecular pharmacology of the haloethyl nitrosoureas: formation of 6-hydroxyethylguanine in DNA treated with BCNU (N,N1-bis[2-chloroethyl]-N-nitrosourea). Biochem Biophys Res Commun. 1981 May 15;100(1):351–357. doi: 10.1016/s0006-291x(81)80103-9. [DOI] [PubMed] [Google Scholar]
  85. Umar A., Boyer J. C., Thomas D. C., Nguyen D. C., Risinger J. I., Boyd J., Ionov Y., Perucho M., Kunkel T. A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994 May 20;269(20):14367–14370. [PubMed] [Google Scholar]
  86. Walker M. D., Hurwitz B. S. BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report. Cancer Chemother Rep. 1970 Aug;54(4):263–271. [PubMed] [Google Scholar]
  87. Weinkam R. J., Lin H. S. Reactions of 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous solution. J Med Chem. 1979 Oct;22(10):1193–1198. doi: 10.1021/jm00196a009. [DOI] [PubMed] [Google Scholar]
  88. Yang J. L., Hsieh F. P., Lee P. C., Tseng H. J. Strand- and sequence-specific attenuation of N-methyl-N'-nitro-N-nitrosoguanidine-induced G.C to A.T transitions by expression of human 6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells. Cancer Res. 1994 Jul 15;54(14):3857–3863. [PubMed] [Google Scholar]
  89. Yarosh D. B. The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res. 1985 Jan-Mar;145(1-2):1–16. doi: 10.1016/0167-8817(85)90034-3. [DOI] [PubMed] [Google Scholar]
  90. Young R. C., DeVita V. T., Jr, Serpick A. A., Canellos G. P. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26;285(9):475–479. doi: 10.1056/NEJM197108262850902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES